Buy HIMS near 25.88 target 32.47 stop loss @ 25.81 Details The technical summary data tells us to buy HIMS near 25.88 with an ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $26.36 which represents a decrease of $-2.19 or -7.67% from the prior close of $28.55. The stock opened at $26.04 and touched a low ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...

It’s that time of the year; We all likely indulged more than we’d like to admit for the holidays and put on a few extra ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...